Wall Street brokerages expect Perrigo Company (NYSE:PRGO) to announce sales of $1.17 billion for the current fiscal quarter, Zacks reports. Twelve analysts have provided estimates for Perrigo’s earnings. The lowest sales estimate is $1.15 billion and the highest is $1.21 billion. Perrigo reported sales of $1.35 billion in the same quarter last year, which would suggest a negative year over year growth rate of 13.3%. The business is scheduled to announce its next earnings results on Thursday, November 9th.

According to Zacks, analysts expect that Perrigo will report full-year sales of $1.17 billion for the current year, with estimates ranging from $4.74 billion to $4.85 billion. For the next year, analysts forecast that the business will report sales of $4.95 billion per share, with estimates ranging from $4.82 billion to $5.06 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Perrigo.

Perrigo (NYSE:PRGO) last posted its quarterly earnings results on Thursday, August 10th. The company reported $1.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.94 by $0.28. Perrigo had a positive return on equity of 11.55% and a negative net margin of 51.04%. The business had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $1.18 billion. During the same quarter in the prior year, the business earned $1.93 EPS. The firm’s revenue for the quarter was down 7.7% on a year-over-year basis.

Several research firms have weighed in on PRGO. Jefferies Group LLC reissued a “hold” rating and issued a $71.00 price objective on shares of Perrigo in a research report on Wednesday, May 24th. Royal Bank Of Canada boosted their price objective on Perrigo from $60.00 to $64.00 and gave the stock an “underperform” rating in a research report on Friday, August 11th. Canaccord Genuity set a $86.00 price objective on Perrigo and gave the stock a “buy” rating in a research report on Monday, May 22nd. Goldman Sachs Group, Inc. (The) reissued a “sell” rating and issued a $68.00 price objective on shares of Perrigo in a research report on Wednesday, May 31st. Finally, Cantor Fitzgerald reissued a “buy” rating on shares of Perrigo in a research report on Monday, August 21st. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and eight have issued a buy rating to the company’s stock. Perrigo presently has an average rating of “Hold” and an average price target of $87.00.

Shares of Perrigo (NYSE:PRGO) opened at 82.79 on Friday. Perrigo has a 1-year low of $63.68 and a 1-year high of $99.14. The company has a 50-day moving average price of $75.91 and a 200-day moving average price of $73.11. The company’s market cap is $11.81 billion.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Friday, August 25th will be paid a $0.16 dividend. The ex-dividend date of this dividend is Wednesday, August 23rd. This represents a $0.64 dividend on an annualized basis and a yield of 0.77%. Perrigo’s dividend payout ratio is currently -3.51%.

In other news, EVP Sharon Kochan sold 1,500 shares of the company’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $79.03, for a total value of $118,545.00. Following the completion of the transaction, the executive vice president now directly owns 10,349 shares in the company, valued at approximately $817,881.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Thomas Farrington sold 616 shares of the company’s stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $76.90, for a total value of $47,370.40. Following the completion of the transaction, the executive vice president now owns 2,724 shares of the company’s stock, valued at $209,475.60. The disclosure for this sale can be found here. Insiders sold a total of 2,981 shares of company stock worth $233,731 over the last 90 days. Corporate insiders own 6.90% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Perrigo by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 14,874,096 shares of the company’s stock worth $1,123,292,000 after purchasing an additional 299,328 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Perrigo by 3,825.1% in the 1st quarter. BlackRock Inc. now owns 12,154,494 shares of the company’s stock worth $806,936,000 after purchasing an additional 11,844,832 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Perrigo by 117.7% in the 2nd quarter. Franklin Resources Inc. now owns 8,109,742 shares of the company’s stock worth $612,448,000 after purchasing an additional 4,383,903 shares in the last quarter. State Street Corp boosted its holdings in shares of Perrigo by 1.7% in the 2nd quarter. State Street Corp now owns 6,757,086 shares of the company’s stock worth $510,294,000 after purchasing an additional 112,287 shares in the last quarter. Finally, Aberdeen Asset Management PLC UK boosted its holdings in shares of Perrigo by 65.2% in the 1st quarter. Aberdeen Asset Management PLC UK now owns 3,028,619 shares of the company’s stock worth $201,070,000 after purchasing an additional 1,195,526 shares in the last quarter. Hedge funds and other institutional investors own 80.36% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/09/perrigo-company-prgo-expected-to-announce-quarterly-sales-of-1-17-billion.html.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.

Get a free copy of the Zacks research report on Perrigo (PRGO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Perrigo Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo Company and related companies with MarketBeat.com's FREE daily email newsletter.